Comparing Oestrogen Receptor Assays in Advanced Breast Cancer
Author Information
Author(s): J.F.R. Robertson, K. Bates, D. Pearson, R.W. Blamey, R.I. Nicholson
Primary Institution: City Hospital, Nottingham; Tenovus Institute, Cardiff, UK
Hypothesis
Can two new oestrogen receptor assays predict response to therapy and survival in advanced breast cancer patients?
Conclusion
The immunocytochemical assay (ICA) is a better predictor of response to endocrine therapy than the enzyme immunoassay (EIA).
Supporting Evidence
- Patients with ER positive tumours survived longer than those with ER negative tumours.
- ER-ICA showed better predictive power for disease progression than ER-EIA.
- Postmenopausal patients had significantly more ER positive tumours than premenopausal patients.
Takeaway
This study looked at two tests to see which one better predicts how well breast cancer patients will respond to treatment. One test was found to be better than the other.
Methodology
The study involved 192 patients with advanced breast cancer, comparing the predictive power of two oestrogen receptor assays (EIA and ICA) for treatment response and survival.
Limitations
The study did not evaluate the assays in a diverse population or consider all potential confounding factors.
Participant Demographics
Patients included both premenopausal and postmenopausal women, with a majority being postmenopausal.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website